SW-100

未知

4-[[6-Chloro-3,4-dihydroquinolin-1(2H)-yl]methyl]-N-hydroxybenzamide | HY-115475 | 4-((6-Chloro-3,4-dihydro-1(2H)-quinolinyl)methyl)-N-hydroxybenzamide | SCHEMBL19260278 | AKOS040742663 | Benzamide, 4-((6-chloro-3,4-dihydro-1(2H)-quinolinyl)methyl)-N-hydr

SW-100

S646609-5mg

5mg

≥99%

-20°C储存

超低温冰袋运输

SW-100, a selective histone deacetylase 6 (HDAC6) inhibitor with an IC 50 of 2.3 nM, shows at least 1000-fold selectivity for HDAC6 relative to all other HDAC isozymes. SW-100 displays a significantly improved ability to cross the blood-brain-barrier In Vitro SW-100 (0.01-10 µM; 48 hours) shows obvious increase in the acetylated α-tubulin levels in a dose-dependent manner. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: HEK293 cells Concentration: 0.01, 0.1, 1, 10 µM Incubation Time: 48 hours Result: Showed obvious increase in the acetylated α-tubulin levels in a dose-dependent manner. In Vivo SW-100 (20 mg/kg; i.p.; twice a day for two days) ameliorates several memory and learning impairments including novel object recognition, temporal ordering, and coordinate and categorical spatial processing in mouse model of Fragile X syndrome . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: 8-10 weeks old C57BL/6 mice ( Fmr1 -/- mice) Dosage: 20 mg/kg Administration: Intraperitoneal injection; twice a day for two days Result: Ameliorated several memory and learning impairments including novel object recognition, temporal ordering, and coordinate and categorical spatial processing in Fmr1 -/- mice。 Form:Solid IC50& Target:HDAC1 5.23 μM (IC 50 ) HDAC2 32.8 μM (IC 50 ) HDAC3 29.5 μM (IC 50 ) HDAC4 10.9 μM (IC 50 ) HDAC5 4.07 μM (IC 50 ) HDAC6 2.3 nM (IC 50 ) HDAC7 4.55 μM (IC 50 ) HDAC8 3.72 μM (IC 50 ) HDAC9 3.46 μM (IC 50 ) HDAC10 26.2 μM (IC 50 ) HDAC11 5.72 μM (IC 50 )

SW-100 是一种选择性组蛋白去乙酰化酶 6 (HDAC6) 抑制剂，其 IC 50 为 2.3 nM，与所有其他 HDAC 同工酶相比，对 HDAC6 的选择性至少提高了 1000 倍。SW-100 穿过血脑屏障的能力明显提高

2126744-35-0

C17H17ClN2O2

316.78 g/mol

130345472

C1CC2=C(C=CC(=C2)Cl)N(C1)CC3=CC=C(C=C3)C(=O)NO

4-[(6-chloro-3,4-dihydro-2H-quinolin-1-yl)methyl]-N-hydroxybenzamide

1S/C17H17ClN2O2/c18-15-7-8-16-14(10-15)2-1-9-20(16)11-12-3-5-13(6-4-12)17(21)19-22/h3-8,10,22H,1-2,9,11H2,(H,19,21)

MNAYBFFSFQRSIT-UHFFFAOYSA-N

C1CC2=C(C=CC(=C2)Cl)N(C1)CC3=CC=C(C=C3)C(=O)NO

130345472

2126744-35-0

4-((6-chloro-3,4-dihydroquinolin-1(2H)-yl)methyl)-N-hydroxybenzamide;SW-100

DMSO : ≥ 125 mg/mL (394.60 mM)

2

3

3

316.098 Da

316.098 Da

52.600 Ų

22

0

385

0

1

3.3